AMPICILLIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Ampicillin Sodium patents expire, and when can generic versions of Ampicillin Sodium launch?
Ampicillin Sodium is a drug marketed by Acs Dobfar Spa, Antibiotice, Apothecon, Consolidated Pharm, Eugia Pharma Speclts, Hikma, Hospira, Hq Speclt Pharma, Intl Medication, Istituto Bio Ita Spa, Lilly, Sagent Pharms Inc, Sandoz, Steriscience, and Watson Labs Inc. and is included in twenty-five NDAs.
The generic ingredient in AMPICILLIN SODIUM is ampicillin sodium. There are seventy drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ampicillin Sodium
A generic version of AMPICILLIN SODIUM was approved as ampicillin sodium by SANDOZ on February 19th, 1987.
Summary for AMPICILLIN SODIUM
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 25 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Clinical Trials: | 11 |
Patent Applications: | 1,859 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AMPICILLIN SODIUM at DailyMed |
Recent Clinical Trials for AMPICILLIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | Phase 2 |
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Alphacait, LLC | Phase 2 |
Pharmacology for AMPICILLIN SODIUM
Drug Class | Penicillin-class Antibacterial |